Abstract: A removable cap for receiving a writing implement includes a reverse clip. The cap has a hollow crown section for receiving the writing implement and an elongate cap extension that extends axially from the hollow crown section and includes an end that terminates in a clip flange. An elongate holding prong projecting substantially perpendicular from the clip flange and extending and opening toward the closed first end of the crown section in substantially parallel-spaced relation to the cap extension so as to define in conjunction with the cap extension and the hollow crown section, an elongate U-shaped slot, which is adapted to snugly engage an attachment material inserted into the slot. A gripping member is located within the U-shaped slot and is configured to intimately engage the attachment material inserted into the slot to assist in maintaining the engagement between the cap and attachment material when the writing implement is removed from the cap.

Abstract: A removable cap for receiving a writing implement includes a reverse clip. The cap has a hollow crown section for receiving the writing implement and an elongate cap extension that extends axially from the hollow crown section and includes an end that terminates in a clip flange. An elongate holding prong projecting substantially perpendicular from the clip flange and extending and opening toward the closed first end of the crown section in substantially parallel-spaced relation to the cap extension so as to define in conjunction with the cap extension and the hollow crown section, an elongate U-shaped slot, which is adapted to snugly engage an attachment material inserted into the slot. A gripping member is located within the U-shaped slot and is configured to intimately engage the attachment material inserted into the slot to assist in maintaining the engagement between the cap and attachment material when the writing implement is removed from the cap.

Abstract: A removable cap for receiving a writing implement includes a reverse clip. The cap has a hollow crown section for receiving the writing implement and an elongate cap extension that extends axially from the hollow crown section and includes an end that terminates in a clip flange. An elongate holding prong projecting substantially perpendicular from the clip flange and extending and opening toward the closed first end of the crown section in substantially parallel-spaced relation to the cap extension so as to define in conjunction with the cap extension and the hollow crown section, an elongate U-shaped slot, which is adapted to snugly engage an attachment material inserted into the slot. A gripping member is located within the U-shaped slot and is configured to intimately engage the attachment material inserted into the slot to assist in maintaining the engagement between the cap and attachment material when the writing implement is removed from the cap.

Abstract: Apparatus for dissipating a fragrance or malodor eliminator utilizes an infused disc which a user can place in either a rotating or a fixed position. The two states will dissipate a scent/malodor-eliminator at different rates. The disc is mounted on a shaft that secures the disc in an air stream. The shaft defines several positions at which the disc can be placed, as well as structures to retain the disc at a selected location along the shaft. The shaft is part of a support which includes a mechanism for securing the apparatus within the air stream. Air flow causes the disc to rotate and dissipate at one rate or to pass through a stationary disc at a second, lower rate, as a function of the position of the disc on the shaft. A method of imparting a scent or malodor eliminator to air is also disclosed.

Abstract: Apparatus for dissipating a fragrance or malodor eliminator utilizes an infused disc which a user can place in either a rotating or a fixed position. The two states will dissipate a scent/malodor-eliminator at different rates. The disc is mounted on a shaft that secures the disc in an air stream. The shaft defines several positions at which the disc can be placed, as well as structures to retain the disc at a selected location along the shaft. The shaft is part of a support which includes a mechanism for securing the apparatus within the air stream. Air flow causes the disc to rotate and dissipate at one rate or to pass through a stationary disc at a second, lower rate, as a function of the position of the disc on the shaft. A method of imparting a scent or malodor eliminator to air is also disclosed.

Abstract: Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.

Abstract: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.

Abstract: Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric.

Abstract: Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.

Abstract: A system for medical imaging is provided and includes at least one neutron generator having a neutron generator fuel material and at least one neutron moderator material, a gantry for stationing an imaging subject, a neutron collimator attached to the neutron generator, the collimator disposed between the neutron moderator and the imaging subject, at least one gamma ray camera electrically connected to a processor-based data acquisition system, and software executing on the processor-based data acquisition system from a non-transitory physical medium, the software providing a first function for producing at least one gamma ray spectrum or image, a second function for applying correction factors to the gamma ray spectra or images, and a third function for analyzing the corrected gamma ray spectra or images to process one or more clinically relevant images of one or more targeted or general areas of the imaging subject.

Abstract: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.

Abstract: A portable system for elemental analysis includes one or more neutron emitters, a chamber for containing a test sample, at least one gamma ray detector electrically connected to a data acquisition system, and software or firmware executing on the data acquisition system from a non-transitory physical medium, the software or firmware providing a first function for producing one or more gamma ray spectrums, a second function for applying correction factors to the one or more gamma ray spectrums, and a third function for analyzing the corrected gamma ray spectrum or spectrums to determine a deconvolved elemental composition of the test sample.

Abstract: Delivery of drugs in association with PLGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units.

Abstract: The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

Abstract: Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Abstract: The present invention provides a process for optimizing the fragrance of a scented cellulosic.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Abstract: Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.